Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus

Abbreviated Report of a WHO Consultation
Executive Summary

This report is an addendum to the diagnostic criteria published in the 2006 WHO/IDF report “Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia”, and addresses the use of HbA1c in diagnosing diabetes mellitus. This report does not invalidate the 2006 recommendations on the use of plasma glucose measurements to diagnose diabetes.

A WHO expert consultation was held from 28 to 30 March 2009. A systematic review was conducted on the use of HbA1c as a diagnostic test for diabetes mellitus. The evidence was summarized and its quality evaluated using the GRADE methodology. The recommendation was formulated and its strength was rated on a two-point scale, based on the quality of evidence and the applicability and performance of the method in different settings.

The WHO Consultation concluded that HbA1c can be used as a diagnostic test for diabetes, provided that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement.

An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value less than 6.5% does not exclude diabetes diagnosed using glucose tests. The expert group concluded that there is currently insufficient evidence to make any formal recommendation on the interpretation of HbA1c levels below 6.5%.

GRADE quality of evidence: moderate
GRADE strength of recommendation: conditional
1. INTRODUCTION

The term diabetes mellitus describes a metabolic disorder with heterogenous aetiologies which is characterized by chronic hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both (1). The long–term relatively specific effects of diabetes include development of retinopathy, nephropathy and neuropathy (2). People with diabetes are also at increased risk of cardiac, peripheral arterial and cerebrovascular disease (3).

Diabetes and lesser forms of glucose intolerance, impaired glucose tolerance (IGT) and impaired fasting glucose (IFG), can now be found in almost every population in the world and epidemiological evidence suggests that, without effective prevention and control programmes, the burden of diabetes is likely to continue to increase globally (4;5).

Because diabetes is now affecting many in the workforce, it has a major and deleterious impact on both individual and national productivity. The socio-economic consequences of diabetes and its complications could have a seriously negative impact on the economies of developed and developing nations (6).

It was against this background that on 20 December, 2006, the United Nations General Assembly unanimously passed Resolution 61/225 declaring diabetes an international public health issue and declaring World Diabetes Day as a United Nations Day.

1.1. Background to current report

WHO has published several guidelines for the diagnosis of diabetes since 1965 (7-10). Both diagnosis and classification were reviewed in 1999 and were published as the guidelines for the Definition, Diagnosis and Classification of Diabetes Mellitus (1).

The potential utility of HbA1c in diabetes care is first mentioned in the 1985 WHO report (9). As more information relevant to the diagnosis of diabetes became available, WHO, with the IDF, convened a joint expert meeting in 2005 to review and update the recommendations on diagnosis only (10). After consideration of the data available and the recommendations made at that time by other international and global organisations, the 2005 consultation made the following recommendations (10):

1. The previous (1999) WHO diagnostic criteria should not be changed.
2. The diagnostic cut-point for IFG (6.1 mmol/l; 110 mg/dl) should not be changed.
3. HbA1c should not be adopted as a diagnostic test, as the challenges of measurement accuracy outweighed the convenience of its use.
The full document can be downloaded from the WHO website:

In March 2009, WHO convened the present consultation in order to update the 1999 and 2006 reports with the place of HbA1c in diagnosing diabetes, based on available evidence.

1.1.1. The update process

The members of the consultation included experts in diabetology, biochemistry, immunology, genetics, epidemiology and public health (Annex 4). The main question to be answered for the update was agreed upon by the expert group:

- How does HbA1c perform in the diagnosis of type 2 diabetes based on the detection and prediction of microvascular complications?

A search for existing systematic reviews in EMBASE and MEDLINE did not identify any relevant systematic review. Therefore, a systematic review to answer this question was conducted by the Boden Institute of Obesity, Nutrition and Exercise, The University of Sydney, Sydney, Australia. The recommendation was drafted by the expert group following the GRADE methodology(11) and the process outlined in the WHO Handbook for Guideline Development. The decision process took into account the findings of the systematic review and the advantages and disadvantages of using HbA1c to diagnose diabetes (Annex 3). The recommendation, quality of evidence and strength of the recommendation were discussed and consensus was reached. All the experts agreed on the recommendation.

The systematic review with GRADE tables is available at
http://www.who.int/topics/diabetes_mellitus/en/

The strength of the recommendation was based on the quality of evidence and feasibility and resource implications for low and middle-income countries. The strength of the recommendation is rated on a two-point scale:

- Weak/conditional: low/moderate/high quality of evidence and/or not applicable at population level in low-resource settings;
- Strong: high/moderate quality of evidence and applicable at population level in low-resource settings.

Diagnostic criteria based on plasma glucose values were reviewed in 2006 and were not revised in this update.

The main question, systematic review and draft recommendation were reviewed by WHO Regional Advisers for noncommunicable diseases and by additional three external experts. The peer reviewers had no disagreement with the recommendation.
Glycated haemoglobin (HbA1c) was initially identified as an “unusual” haemoglobin in patients with diabetes over 40 years ago (12). After that discovery, numerous small studies were conducted correlating it to glucose measurements resulting in the idea that HbA1c could be used as an objective measure of glycaemic control. The A1C-Derived Average Glucose (ADAG) study included 643 participants representing a range of A1C levels. It established a validated relationship between A1C and average glucose across a range of diabetes types and patient populations (13). HbA1c was introduced into clinical use in the 1980s and subsequently has become a cornerstone of clinical practice (14).

HbA1c reflects average plasma glucose over the previous eight to 12 weeks (15). It can be performed at any time of the day and does not require any special preparation such as fasting. These properties have made it the preferred test for assessing glycaemic control in people with diabetes. More recently, there has been substantial interest in using it as a diagnostic test for diabetes and as a screening test for persons at high risk of diabetes (16).

Owing in large part to the inconvenience of measuring fasting plasma glucose levels or performing an OGTT, and day-to-day variability in glucose, an alternative to glucose measurements for the diagnosis of diabetes has long been sought. HbA1c has now been recommended by an International Committee and by the ADA as a means to diagnose diabetes (16). Although it gives equal or almost equal sensitivity and specificity to a fasting or post-load glucose measurement as a predictor of prevalent retinopathy (17), it is not available in many parts of the world. Also, many people identified as having diabetes based on HbA1c will not have diabetes by direct glucose measurement.

Recommendation

HbA1c can be used as a diagnostic test for diabetes providing that stringent quality assurance tests are in place and assays are standardised to criteria aligned to the international reference values, and there are no conditions present which preclude its accurate measurement.

An HbA1c of 6.5% is recommended as the cut point for diagnosing diabetes. A value of less than 6.5% does not exclude diabetes diagnosed using glucose tests.

Quality of evidence assessed by GRADE: moderate

Strength of recommendation based on GRADE criteria: conditional
and vice versa.

The relationship between HbA1c and prevalent retinopathy is similar to that of plasma glucose, whether glucose and HbA1c are plotted in deciles (18), in vigintiles (Figure 1) or as continuous variables (Figure 2). This relationship was originally reported in the Pima Indians (19) and has also been observed in several other populations including Egyptians (20), the NHANES study in the USA (21), in Japanese (22) and more recently in the DETECT-2 analysis (Figures 1 and 2). Overall, the performance of HbA1c has been similar to that of fasting or 2-h plasma glucose. For all three measures of glycaemia, the value above which the prevalence of retinopathy begins to rise rapidly has differed to some extent between studies. Although HbA1c gives equal or almost equal sensitivity and specificity to glucose measurement as a predictor of prevalent retinopathy, it is not available in many parts of the world and in general, it is not known which is the better for predicting microvascular complications.

It is unclear whether HbA1c or blood glucose is better for predicting the development of retinopathy, but a recent report from Australia has shown that a model including HbA1c for predicting incident retinopathy is as good as or possibly better than one including fasting plasma glucose (23).

The use of HbA1c can avoid the problem of day-to-day variability of glucose values, and importantly it avoids the need for the person to fast and to have preceding dietary preparations. These advantages have implications for early identification and treatment which have been strongly advocated in recent years.

However, HbA1c may be affected by a variety of genetic, haematologic and illness-related factors (Annex 1) (24). The most common important factors worldwide affecting HbA1c levels are haemoglobinopathies (depending on the assay employed), certain anaemias, and disorders associated with accelerated red cell turnover such as malaria (16;25).

The utility and convenience of HbA1c compared with measures of plasma glucose for the diagnosis of diabetes needs to be balanced against the fact that it is unavailable in many countries, despite being a recognized valuable tool in diabetes management. In addition the HbA1c assay is not currently well enough standardized in many countries for its use to be recommended universally at this time. However, there will be countries where optimal circumstances already exist for its use. Factors influencing HbA1c assays are presented in Annex 2 and 3.

There are aspects of the measurement of HbA1c that are problematic. Although in some laboratories the precision of HbA1c measurement is similar to that of plasma glucose, global consistency with both assays remains a problem (16). Whether it is the glucose or HbA1c assay that is used, consistent and comparable data that meet international standards are required. This is starting to happen in many countries but obviously is still not standard across the world. Within any country, it is axiomatic that results for glucose and HbA1c should be consistent between laboratories.
The National Glycohemoglobin Standardization Program (NGSP) (26) was established following the completion of the Diabetes Complications and Control Trial (DCCT). For many years it was the sole basis for improved harmonization of HbA1c assays. More recently the International Federation of Clinical Chemists (IFCC) established a working group on HbA1c in an attempt to introduce an international standardization program (27). An important part of this effort was establishment of reference method procedures for HbA1c. Currently, both the NGSP and the IFCC base their evaluations on reference method procedures that have further enhanced the harmonization of HbA1c assays across manufacturers. Finally in the USA, the College of American Pathologists (CAP) has mandated more stringent criteria for individual assays to match assigned values for materials provided in the CAP proficiency programme (28).

A further major factor concerns costs and availability of HbA1c assays in many countries. Also, the situation in several of these countries will be exacerbated by high prevalences of conditions such as haemoglobinopathies, which affect HbA1c measurement, as discussed earlier.

A report published in 2009 by an International Expert Committee on the role of HbA1c in the diagnosis of diabetes recommended that HbA1c can be used to diagnose diabetes and that the diagnosis can be made if the HbA1c level is \( \geq 6.5\% \) (16). Diagnosis should be confirmed with a repeat HbA1c test, unless clinical symptoms and plasma glucose levels \( >11.1\text{mmol/l} \) (200 mg/dl) are present in which case further testing is not required. Levels of HbA1c just below 6.5% may indicate the presence of intermediate hyperglycaemia. The precise lower cut-off point for this has yet to be defined, although the ADA has suggested 5.7 – 6.4% as the high risk range (29). While recognizing the continuum of risk that may be captured by the HbA1c assay, the International Expert Committee recommended that persons with a HbA1c level between 6.0 and 6.5% were at particularly high risk and might be considered for diabetes prevention interventions.

The WHO consultation reviewed the evidence on the relationship between HbA1c and prevalent and incident microvascular complications presented in the systematic review. Tables 1 and 2 show HbA1c and glucose cut-off points associated with prevalent and incident microvascular complications in available studies. GRADE tables of evidence are presented in Tables 3 and 4. In view of the above and of the advances in technology over recent years, members of the consultation agreed that HbA1c may be used to diagnose diabetes providing that appropriate conditions apply, i.e. standardized assay, low coefficient of variability, and calibration against IFCC standards. Furthermore, each country should decide whether it is appropriate for its own circumstances. The choice of diagnostic method will depend on local considerations such as cost, availability of equipment, population characteristics, presence of a national quality assurance system etc. Policy-makers are advised to ensure that accurate blood glucose measurement be generally available at the primary health care level, before introducing HbA1c measurement as a diagnostic test. The consultation concluded that there is insufficient evidence to make any formal
recommendation on the interpretation of HbA1c levels below 6.5%.

Long term prospective studies are required in all major ethnic groups to establish more precisely the glucose and HbA1c levels predictive of microvascular and macrovascular complications. A working group should be established to examine all aspects of HbA1c and glucose measurement methodology.

The diagnosis of diabetes in an asymptomatic person should not be made on the basis of a single abnormal plasma glucose or HbA1c value. At least one additional HbA1c or plasma glucose test result with a value in the diabetic range is required, either fasting, from a random (casual) sample, or from the oral glucose tolerance test (OGTT). The diagnosis should be made by the best technology available, avoiding blood glucose monitoring meters and single-use HbA1c test kits (except where this is the only option available or where there is a stringent quality assurance programme in place).

It is advisable to use one test or the other but if both glucose and HbA1c are measured and both are “diagnostic” then the diagnosis is made. If one only is abnormal then a further abnormal test result, using the same method, is required to confirm the diagnosis.

More and more asymptomatic subjects are being detected as a result of screening programmes so that diagnostic certainty is paramount. If such tests fail to confirm the diagnosis of diabetes, it will usually be advisable to maintain surveillance with periodic re–testing until the glycaemic status becomes clear.
Figure 1. Prevalence of diabetes-specific retinopathy (≥ moderate non proliferative retinopathy) by vigintiles\* of distribution of FPG, 2-h PG and HbA1c from DETECT-2.

\*20 equally-sized groups.
Figure 2. Prevalence of retinopathy by 0.5 mmol/L intervals for FPG and 2-h PG and by 0.5% intervals for HbA1c for any retinopathy and diabetes-specific retinopathy (≥ moderate NPDR) from DETECT-2
Table 1. HbA1c, FPG and 2-h PG cut-points associated with prevalent microvascular complications

<table>
<thead>
<tr>
<th>Study</th>
<th>Complication</th>
<th>HbA1c</th>
<th>FPG</th>
<th>2-h PG</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Optimum cut-point (%)</td>
<td>Sensitivity (%)</td>
<td>Specificity (%)</td>
<td>Optimum cut-point (mmol/L)</td>
</tr>
<tr>
<td>Colagiuri et al.</td>
<td>Retinopathy (ROC curve analysis)</td>
<td>≥6.3</td>
<td>0.90</td>
<td>86</td>
</tr>
<tr>
<td>Colagiuri et al.</td>
<td>Retinopathy (visual inspection of decile distribution)</td>
<td>6.4-6.8</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Engelgau et al. (1997)</td>
<td>Bi-modal: Entire population</td>
<td>≥6.7</td>
<td>NR</td>
<td>68</td>
</tr>
<tr>
<td>Expert Committee, (1997)</td>
<td>Retinopathy</td>
<td>≥6.2</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Ito et al. (2000a)</td>
<td>Retinopathy</td>
<td>≥7.3</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>McCance et al. (1994)</td>
<td>Retinopathy</td>
<td>≥7.0</td>
<td>NR</td>
<td>78</td>
</tr>
<tr>
<td>WHO equivalent</td>
<td></td>
<td>≥6.1</td>
<td>NR</td>
<td>81</td>
</tr>
<tr>
<td>ROC curve analysis</td>
<td></td>
<td>≥5.7</td>
<td>0.95</td>
<td>87</td>
</tr>
<tr>
<td>Miyazaki et al. (2004)</td>
<td>Retinopathy</td>
<td>≥5.8</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>Tapp et al. (2006)</td>
<td>Retinopathy</td>
<td>≥6.1</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Microalbuminuria</td>
<td>≥6.1</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Retinopathy§</td>
<td>≥6.0</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td></td>
<td>Microalbuminuria</td>
<td>NIL</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

* Significantly different from HbA1c (p < 0.01);  # Median decile value 2-h PG = 2 hour plasma glucose; AROC = Area under the receiver operator characteristic curve; FPG = fasting plasma glucose; NR = Not reported; ROC = receiver operator characteristic; § By change point analysis; WHO = World Health Organization.
Table 2. HbA1c and FPG cut-points associated with incident diabetes complications

<table>
<thead>
<tr>
<th>Study</th>
<th>Complication</th>
<th>HbA1c</th>
<th>FPG</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Optimum cut-point (%)</td>
<td>AROC</td>
</tr>
<tr>
<td>Massin et al. (in press, Archives of Ophthalmol)</td>
<td>Retinopathy</td>
<td>≥ 6.0</td>
<td>NR</td>
</tr>
</tbody>
</table>

AROC = Area under the receiver operator characteristic curve; FPG = fasting plasma glucose; NR = Not reported.
Table 3. GRADE table for HbA1c and detection of prevalent microvascular complications

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No. of studies</th>
<th>Study design</th>
<th>Factors that may decrease quality of evidence</th>
<th>Final quality</th>
<th>Effect per 10001</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td>True positives (patients with prevalent complications)</td>
<td>3 studies$^7$ (31 797 patients)</td>
<td>Observational</td>
<td>None$^3$ None None None Unlikely</td>
<td>⊗⊗⊗Ο moderate</td>
<td>Prev 80%: 672 Prev 40%: 336 Prev 10%: 84</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>True negatives (patients without prevalent complications)</td>
<td>3 (31 797 patients)</td>
<td>Observational</td>
<td>None$^3$ None None None Unlikely</td>
<td>⊗⊗Ο moderate</td>
<td>Prev 80%: 172 Prev 40%: 516 Prev 10%: 774</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>False positives (patients incorrectly classified as having prevalent complications)</td>
<td>3 (31 797 patients)</td>
<td>Observational</td>
<td>None$^3$ None None None Unlikely</td>
<td>⊗⊗Ο moderate</td>
<td>Prev 80%: 28 Prev 40%: 84 Prev 10%: 126</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>False negatives (patients incorrectly classified as not having prevalent complications)</td>
<td>3 (31 797 patients)</td>
<td>Observational</td>
<td>None$^3$ None None None Unlikely</td>
<td>⊗⊗Ο moderate</td>
<td>Prev 80%: 128 Prev 40%: 64 Prev 10%: 16</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>Inconclusive $^4$</td>
<td>4 studies (19 142 patients)</td>
<td>Observational</td>
<td>– – – – – –</td>
<td>– –</td>
<td>– –</td>
<td>IMPORTANT</td>
</tr>
<tr>
<td>Cost</td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

1 Based on combined sensitivity of 84% and specificity of 86%.
2 One study contained pooled data from eight studies with 29 819 participants.
3 Although not a serious limitation, one study oversampled people with known diabetes.
4 These four studies did not report information on sensitivity and specificity of HbA1c for predicting prevalent microvascular complications.
Table 4. GRADE table for HbA1c and incident microvascular complications

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No. of studies</th>
<th>Study design</th>
<th>Factors that may decrease quality of evidence</th>
<th>Final quality</th>
<th>Effect per 10002</th>
<th>Importance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Limitations</td>
<td>Indirectness</td>
<td>Inconsistency</td>
<td>Imprecision</td>
</tr>
<tr>
<td>True positives (patients with incident complications)</td>
<td>1 study (700 patients)</td>
<td>Observational</td>
<td>None</td>
<td>None</td>
<td>N/A²</td>
<td>Not assessable³</td>
</tr>
<tr>
<td>True negatives (patients without incident complications)</td>
<td>1 (700 patients)</td>
<td>Observational</td>
<td>None</td>
<td>None</td>
<td>N/A²</td>
<td>Not assessable³</td>
</tr>
<tr>
<td>False positives (patients incorrectly classified as having incident complications)</td>
<td>1 (700 patients)</td>
<td>Observational</td>
<td>None</td>
<td>None</td>
<td>N/A²</td>
<td>Not assessable³</td>
</tr>
<tr>
<td>False negatives (patients incorrectly classified as not having incident complications)</td>
<td>1 (700 patients)</td>
<td>Observational</td>
<td>None</td>
<td>None</td>
<td>N/A²</td>
<td>Not assessable³</td>
</tr>
<tr>
<td>Inconclusive ⁴</td>
<td>1 study (233 patients)</td>
<td>Observational</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Cost</td>
<td>Not reported</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

² Based on combined sensitivity of 16% and specificity of 97%.
²² Imprecision could not be assessed as confidence intervals were not reported.
³ Inconsistency is not applicable with data from only one study.
⁴ This study did not report information on sensitivity and specificity of HbA1c for predicting incident microvascular complications.
Annex 1

Some of the factors that influence HbA1c and its measurement*. Adapted from Gallagher et al (24)

| 1. Erythropoiesis  | Increased HbA1c: iron, vitamin B12 deficiency, decreased erythropoiesis. Decreased HbA1c: administration of erythropoietin, iron, vitamin B12, reticulocytosis, chronic liver disease. |
| 2. Altered Haemoglobin | Genetic or chemical alterations in haemoglobin: haemoglobinopathies, HbF, methaemoglobin, may increase or decrease HbA1c. |
| 4. Erythrocyte destruction | Increased HbA1c: increased erythrocyte life span: Splenectomy. Decreased A1c: decreased erythrocyte life span: haemoglobinopathies, splenomegaly, rheumatoid arthritis or drugs such as antiretrovirals, ribavirin and dapsone. |

* Some of the above interfering factors are “invisible” in certain of the available assays.
Annex 2

Advantages and disadvantages of various HbA1c assay methods

<table>
<thead>
<tr>
<th>Assay</th>
<th>Principle</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ion Exchange Chromatography</td>
<td>HbA1c has lower isoelectric point and migrates faster than other Hb components.</td>
<td>Can inspect chromograms for Hb variants. Measurements with great precision.</td>
<td>Variable interference from hemoglobinopathies, HbF and carbamylated Hb but the current ion exchange assays correct for HbF and carbamylated Hb does not interfere.</td>
</tr>
<tr>
<td>Boronate Affinity</td>
<td>Glucose binds to m-aminophenylboronic acid.</td>
<td>Minimal interference from haemoglobinopathies, HbF and carbamylated Hb.</td>
<td>Measures not only glycation of N-terminal valine on β chain, but also β chains glycated at other sites and glycated α chains.</td>
</tr>
<tr>
<td>Immunoassays</td>
<td>Antibody binds to glucose and between 4-10 N-terminal amino acids on β chain.</td>
<td>Not affected by HbE, HbD or carbamylated Hb Relatively easy to implement under many different formats.</td>
<td>May be affected by haemoglobinopathies with altered amino acids on binding sites. Some interference with HbF.</td>
</tr>
</tbody>
</table>
Annex 3

Advantages and disadvantage of assays for glucose and HbA1c

<table>
<thead>
<tr>
<th></th>
<th>Glucose</th>
<th>HbA1c</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Patient preparation prior to collection of blood</strong></td>
<td>Stringent requirements if measured for diagnostic purposes.</td>
<td>None.</td>
</tr>
<tr>
<td><strong>Processing of blood</strong></td>
<td>Stringent requirements for rapid processing, separation and storage of plasma or serum minimally at 4 °C.</td>
<td>Avoid conditions for more than 12hr at temperatures &gt;23°C. Otherwise keep at 4°C (stability minimally 1 week).</td>
</tr>
<tr>
<td><strong>Measurement</strong></td>
<td>Widely available</td>
<td>Not readily available worldwide</td>
</tr>
<tr>
<td><strong>Standardization</strong></td>
<td>Standardized to reference method procedures.</td>
<td>Standardized to reference method procedures.</td>
</tr>
<tr>
<td><strong>Routine calibration</strong></td>
<td>Adequate.</td>
<td>Adequate.</td>
</tr>
<tr>
<td><strong>Interferences: illness</strong></td>
<td>Severe illness may increase glucose concentration.</td>
<td>Severe illness may shorten red-cell life and artifactually reduce HbA1c values.</td>
</tr>
<tr>
<td><strong>Haemoglobinopathies</strong></td>
<td>Little problem unless the patient is ill.</td>
<td>May interfere with measurement in some assays.</td>
</tr>
<tr>
<td><strong>Haemoglobinopathy traits</strong></td>
<td>No problems.</td>
<td>Most assays are not affected.</td>
</tr>
<tr>
<td><strong>Affordability</strong></td>
<td>Affordable in most low and middle income country settings.</td>
<td>Unaffordable in most low and middle-income country settings.</td>
</tr>
</tbody>
</table>
Annex 4

External experts

Dr Monira AL AROUJ
Dasman Center for Research and Treatment of Diabetes
Kuwait City
Kuwait
Area of expertise: diabetes management

Dr George ALBERTI
Endocrinology and Metabolic Medicine
Imperial College, London
United Kingdom
Area of expertise: biochemical tests, standardization of laboratory methods

Dr Stephen COLAGIURI
Boden Institute of Obesity, Nutrition and Exercise
The University of Sydney
Australia
Area of expertise: diabetes and metabolism, guideline development

Dr Earl FORD
Centers for Disease Control and Prevention
Atlanta
United States of America
Area of expertise: diabetes epidemiology

Dr Andrew HATTERSLEY
Institute of Biomedical and Clinical Science Peninsula Medical School
Exeter
United Kingdom
Area of expertise: molecular genetics of diabetes

Dr Takashi KADOWAKI
Graduate School of Medicine
University of Tokyo
Japan
Area of expertise: genetics of diabetes

Dr Åke LERNMARK
Lund University/CRC and TEDDY-Sweden
Department of Clinical Sciences
Malmö
Sweden
Area of expertise: immunogenetics of diabetes

Dr LINONG Ji
Peking University People’s Hospital
Department of Endocrinology and Metabolism
Beijing
China
Area of expertise: diabetes management
Dr Ayesha MOTALA
Nelson R. Mandela School of Medicine University of Kwazulu-Natal
Department of Diabetes and Endocrinology
Durban
South Africa
Area of expertise: diabetes in sub-Saharan Africa

Dr David NATHAN
Diabetes Center
Massachusetts General Hospital
Harvard Medical School
Boston
United States of America
Area of expertise: diagnostic criteria for diabetes

Dr Ambady RAMACHANDRAN
India Diabetes Research Foundation
Chennai
India
Area of expertise: diabetes in South-East Asia

Dr Maria-Inès SCHMIDT
Universidade Federal do Rio Grande do Sul
Porto Alegre
Brazil
Area of expertise: diabetes epidemiology, diabetes and pregnancy

Dr Jonathan SHAW
Baker IDI and Diabetes Institute
Caulfield
Australia
Area of expertise: diabetes epidemiology

Dr Martin SILINK
International Diabetes Federation
Brussels
Belgium
Area of expertise: diabetes in children

Dr Jan SKRHA
Charles University in Prague
First Faculty of Medicine
Prague
Czech Republic
Area of expertise: diabetes management

Dr Eugene SOBNGWI
Faculty of Medicine and Biomedical Sciences
University of Yaoundé 1
Cameroon
Area of expertise: diabetes with unusual clinical presentation

Dr Michael STEFFES
University of Minnesota
Minneapolis
United States of America
Area of expertise: clinical biochemistry, performance and standardization of HbA1c test
Dr Jaakko TUOMILEHTO  
University of Helsinki  
Department of Public Health  
Helsinki  
Finland  
*Area of expertise:* epidemiology and public health, diabetes prevention

Dr Pnina VARDI  
Tel Aviv University  
Faculty of Medicine  
Tel Aviv  
Israel  
*Area of expertise:* diabetes in children

Dr Nicholas WAREHAM  
MRC Epidemiology Unit  
Institute of Metabolic Science  
Cambridge  
United Kingdom  
*Area of expertise:* public health interventions, screening for diabetes

Dr Paul ZIMMET  
Baker IDI Heart and Diabetes Institute  
Caulfield  
Australia  
*Area of expertise:* diabetes epidemiology, diagnostic criteria for diabetes

**WHO Secretariat**

Dr Ala ALWAN  
Assistant Director-General,  
Noncommunicable Diseases and Mental Health

Dr Fiona ADSHEAD  
Director,  
Chronic Diseases and Health Promotion

Dr Shanthi P.B. MENDIS  
Coordinator,  
Chronic Diseases Prevention and Management

Dr Gojka ROGLIC  
Medical Officer,  
Chronic Diseases Prevention and Management

Dr Alberto BARCELO  
Regional Adviser  
Regional Office for the Americas

*Declaration of interest*

All invited experts and external reviewers were requested to complete a Declaration of Interests form prior to the meeting or review. The declared interest was cleared through the WHO Office of the Legal Counsel.
Nine out of a total of 21 invited experts declared an interest in the subject matter of the meeting, as follows:

Dr K. G. M. M. Alberti has performed paid consultancies for AstraZeneca, ResMed Inc, Smith Kline Beecham, Boehringer Ingelheim, Merck, Pfizer, MSD, Solvay and Servier.

Dr A. Lernmark’s institution has received financial remuneration from Diamyd Medical AB for performing molecular analyses in Phase II clinical trials.

Dr Linong Ji is a member of the American Diabetes Association, European Association for the Study of Diabetes, and International Diabetes Federation Expert Committee for the Diagnosis of Diabetes.

Dr A. Motala’s travel to diabetes congresses has been paid by Servier, Novo Nordisk, and Sanofi-Aventis.

Dr D. Nathan’s institution has received research grants on insulin use from Sanofi-Aventis.

Dr J. Shaw is a member of advisory boards of Merck Sharp Dhome, Eli Lilly and Jansen Cilag. He has received lecture fees from Pfizer and GlaxoSmithKline. His department is receiving research funding from GlaxoSmithKline, Pfizer, Eli Lilly, Novo Nordisk, MSD, Astra Zeneca, BMS and Sanofi-Aventis.

Dr J. Skrha’s institution has received a research grant from Eli Lilly. His travel to diabetes congresses has occasionally been paid by Novartis, GSK and Eli Lilly.

Dr M. Steffes has performed a paid consultancy for Glaxo Smith Kline.

Dr J. Tuomilehto has performed paid consultancies for AstraZeneca, Bayer Schering Pharma, Merck, Novartis and Novo Nordisk.

Since the declared interests were not directly related to the topic of this guideline, it was decided that all of the above-mentioned experts could participate, subject to the public disclosure of their interests.

Funding sources

The guideline was funded by a grant from the Government of Japan.

Implementation

It is recognized that the implementation of the new diagnostic method may be challenging in many settings. WHO will provide technical advice to assist the decision process in countries.

Future updates

As with all recommendations to date, it is likely that further research will necessitate modifications of the present recommendation. This document will be reviewed in five years, pending availability of appropriate resources.
Reference List


